Cargando…
Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis
Background and Objectives: To assess the effects of fosfomycin compared with other antibiotics as a prophylaxis for urinary tract infections (UTIs) in men undergoing transrectal prostate biopsies. Materials and Methods: We searched multiple databases and trial registries without publication language...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221023/ https://www.ncbi.nlm.nih.gov/pubmed/37241143 http://dx.doi.org/10.3390/medicina59050911 |
_version_ | 1785049357459914752 |
---|---|
author | Gu, Hui Mo Gu, Jin Seok Chung, Ho Seok Jung, Seung Il Kwon, Dongdeuk Kim, Myung Ha Jung, Jae Hung Han, Mi Ah Kang, Seung Ji Hwang, Eu Chang Dahm, Philipp |
author_facet | Gu, Hui Mo Gu, Jin Seok Chung, Ho Seok Jung, Seung Il Kwon, Dongdeuk Kim, Myung Ha Jung, Jae Hung Han, Mi Ah Kang, Seung Ji Hwang, Eu Chang Dahm, Philipp |
author_sort | Gu, Hui Mo |
collection | PubMed |
description | Background and Objectives: To assess the effects of fosfomycin compared with other antibiotics as a prophylaxis for urinary tract infections (UTIs) in men undergoing transrectal prostate biopsies. Materials and Methods: We searched multiple databases and trial registries without publication language or status restrictions until 4 January 2022. Parallel-group randomized controlled trials (RCTs) and non-randomized studies (NRS) were included. The primary outcomes were febrile UTI, afebrile UTI, and overall UTI. We used GRADE guidance to rate the certainty of evidence of RCTs and NRSs. The protocol was registered with PROSPERO (CRD42022302743). Results: We found data on five comparisons; however, this abstract focuses on the primary outcomes of the two most clinically relevant comparisons. Regarding fosfomycin versus fluoroquinolone, five RCTs and four NRSs with a one-month follow-up were included. Based on the RCT evidence, fosfomycin likely resulted in little to no difference in febrile UTIs compared with fluoroquinolone. This difference corresponded to four fewer febrile UTIs per 1000 patients. Fosfomycin likely resulted in little to no difference in afebrile UTIs compared with fluoroquinolone. This difference corresponded to 29 fewer afebrile UTIs per 1000 patients. Fosfomycin likely resulted in little to no difference in overall UTIs compared with fluoroquinolone. This difference corresponded to 35 fewer overall UTIs per 1000 patients. Regarding fosfomycin and fluoroquinolone combined versus fluoroquinolone, two NRSs with a one- to three-month follow-up were included. Based on the NRS evidence, fosfomycin and fluoroquinolone combined may result in little to no difference in febrile UTIs compared with fluoroquinolone. This difference corresponded to 16 fewer febrile UTIs per 1000 patients. Conclusions: Compared with fluoroquinolone, fosfomycin or fosfomycin and fluoroquinolone combined may have a similar prophylactic effect on UTIs after a transrectal prostate biopsy. Given the increasing fluoroquinolone resistance and its ease to use, fosfomycin may be a good option for antibiotic prophylaxis. |
format | Online Article Text |
id | pubmed-10221023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102210232023-05-28 Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis Gu, Hui Mo Gu, Jin Seok Chung, Ho Seok Jung, Seung Il Kwon, Dongdeuk Kim, Myung Ha Jung, Jae Hung Han, Mi Ah Kang, Seung Ji Hwang, Eu Chang Dahm, Philipp Medicina (Kaunas) Systematic Review Background and Objectives: To assess the effects of fosfomycin compared with other antibiotics as a prophylaxis for urinary tract infections (UTIs) in men undergoing transrectal prostate biopsies. Materials and Methods: We searched multiple databases and trial registries without publication language or status restrictions until 4 January 2022. Parallel-group randomized controlled trials (RCTs) and non-randomized studies (NRS) were included. The primary outcomes were febrile UTI, afebrile UTI, and overall UTI. We used GRADE guidance to rate the certainty of evidence of RCTs and NRSs. The protocol was registered with PROSPERO (CRD42022302743). Results: We found data on five comparisons; however, this abstract focuses on the primary outcomes of the two most clinically relevant comparisons. Regarding fosfomycin versus fluoroquinolone, five RCTs and four NRSs with a one-month follow-up were included. Based on the RCT evidence, fosfomycin likely resulted in little to no difference in febrile UTIs compared with fluoroquinolone. This difference corresponded to four fewer febrile UTIs per 1000 patients. Fosfomycin likely resulted in little to no difference in afebrile UTIs compared with fluoroquinolone. This difference corresponded to 29 fewer afebrile UTIs per 1000 patients. Fosfomycin likely resulted in little to no difference in overall UTIs compared with fluoroquinolone. This difference corresponded to 35 fewer overall UTIs per 1000 patients. Regarding fosfomycin and fluoroquinolone combined versus fluoroquinolone, two NRSs with a one- to three-month follow-up were included. Based on the NRS evidence, fosfomycin and fluoroquinolone combined may result in little to no difference in febrile UTIs compared with fluoroquinolone. This difference corresponded to 16 fewer febrile UTIs per 1000 patients. Conclusions: Compared with fluoroquinolone, fosfomycin or fosfomycin and fluoroquinolone combined may have a similar prophylactic effect on UTIs after a transrectal prostate biopsy. Given the increasing fluoroquinolone resistance and its ease to use, fosfomycin may be a good option for antibiotic prophylaxis. MDPI 2023-05-10 /pmc/articles/PMC10221023/ /pubmed/37241143 http://dx.doi.org/10.3390/medicina59050911 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Gu, Hui Mo Gu, Jin Seok Chung, Ho Seok Jung, Seung Il Kwon, Dongdeuk Kim, Myung Ha Jung, Jae Hung Han, Mi Ah Kang, Seung Ji Hwang, Eu Chang Dahm, Philipp Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis |
title | Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis |
title_full | Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis |
title_fullStr | Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis |
title_short | Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis |
title_sort | fosfomycin for antibiotic prophylaxis in men undergoing a transrectal prostate biopsy: a systematic review and meta-analysis |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221023/ https://www.ncbi.nlm.nih.gov/pubmed/37241143 http://dx.doi.org/10.3390/medicina59050911 |
work_keys_str_mv | AT guhuimo fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT gujinseok fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT chunghoseok fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT jungseungil fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT kwondongdeuk fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT kimmyungha fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT jungjaehung fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT hanmiah fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT kangseungji fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT hwangeuchang fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis AT dahmphilipp fosfomycinforantibioticprophylaxisinmenundergoingatransrectalprostatebiopsyasystematicreviewandmetaanalysis |